Cargando…

Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy

Therapeutic application of unmodified camptothecin (CPT) is severely restricted by its extremely low water solubility and the instability of active lactone ring. In this study, a redox-sensitive CPT-OA conjugate containing the disulfide bond (CPT-SS-OA) was used to deliver the lactone-stabilized CPT...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fu, Huang, Zhao, Chen, Huitong, Yan, Lu, Li, Jin, Su, Yue, Zhang, Qian, Huang, Zhengye, Zheng, Yaxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882494/
https://www.ncbi.nlm.nih.gov/pubmed/31735094
http://dx.doi.org/10.1080/10717544.2019.1678696
_version_ 1783474174393581568
author Li, Fu
Huang, Zhao
Chen, Huitong
Yan, Lu
Li, Jin
Su, Yue
Zhang, Qian
Huang, Zhengye
Zheng, Yaxin
author_facet Li, Fu
Huang, Zhao
Chen, Huitong
Yan, Lu
Li, Jin
Su, Yue
Zhang, Qian
Huang, Zhengye
Zheng, Yaxin
author_sort Li, Fu
collection PubMed
description Therapeutic application of unmodified camptothecin (CPT) is severely restricted by its extremely low water solubility and the instability of active lactone ring. In this study, a redox-sensitive CPT-OA conjugate containing the disulfide bond (CPT-SS-OA) was used to deliver the lactone-stabilized CPT for the improved antitumor efficacy. A non-sensitive CPT-OA was used as control to illuminate the role of disulfide bond. Both CPT-SS-OA and CPT-OA formulated in cremophor EL micelles (CM) displayed multiple therapeutic advantages: small diameter (∼14 nm), efficient cellular internalization, prolonged blood circulation, and favorable biodistribution. However, only CPT-SS-OA/CM achieved the superior chemotherapeutic efficacy over CPT solution in the Lewis lung carcinoma (LLC) cancer xenograft, which was ascribed to the accelerated release of the active lactone CPT responding to the elevated reductive glutathione in tumor cells. Such redox-sensitive lipophilic prodrugs represent an effective alternative strategy for the delivery of CPT in the active lactone form. This strategy can be used for other chemically unstable chemotherapeutant for the improved therapeutic efficacies.
format Online
Article
Text
id pubmed-6882494
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-68824942019-12-09 Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy Li, Fu Huang, Zhao Chen, Huitong Yan, Lu Li, Jin Su, Yue Zhang, Qian Huang, Zhengye Zheng, Yaxin Drug Deliv Research Article Therapeutic application of unmodified camptothecin (CPT) is severely restricted by its extremely low water solubility and the instability of active lactone ring. In this study, a redox-sensitive CPT-OA conjugate containing the disulfide bond (CPT-SS-OA) was used to deliver the lactone-stabilized CPT for the improved antitumor efficacy. A non-sensitive CPT-OA was used as control to illuminate the role of disulfide bond. Both CPT-SS-OA and CPT-OA formulated in cremophor EL micelles (CM) displayed multiple therapeutic advantages: small diameter (∼14 nm), efficient cellular internalization, prolonged blood circulation, and favorable biodistribution. However, only CPT-SS-OA/CM achieved the superior chemotherapeutic efficacy over CPT solution in the Lewis lung carcinoma (LLC) cancer xenograft, which was ascribed to the accelerated release of the active lactone CPT responding to the elevated reductive glutathione in tumor cells. Such redox-sensitive lipophilic prodrugs represent an effective alternative strategy for the delivery of CPT in the active lactone form. This strategy can be used for other chemically unstable chemotherapeutant for the improved therapeutic efficacies. Taylor & Francis 2019-11-18 /pmc/articles/PMC6882494/ /pubmed/31735094 http://dx.doi.org/10.1080/10717544.2019.1678696 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Fu
Huang, Zhao
Chen, Huitong
Yan, Lu
Li, Jin
Su, Yue
Zhang, Qian
Huang, Zhengye
Zheng, Yaxin
Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
title Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
title_full Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
title_fullStr Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
title_full_unstemmed Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
title_short Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
title_sort redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882494/
https://www.ncbi.nlm.nih.gov/pubmed/31735094
http://dx.doi.org/10.1080/10717544.2019.1678696
work_keys_str_mv AT lifu redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT huangzhao redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT chenhuitong redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT yanlu redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT lijin redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT suyue redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT zhangqian redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT huangzhengye redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy
AT zhengyaxin redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy